Open AccessRANIBIZUMAB 0.5 MG TREATMENT IN ADOLESCENTS WITH CHOROIDAL NEOVASCULARIZATION: SUBGROUP ANALYSIS DATA FROM THE MINERVA STUDY
Author(s) -
Philip Hykin,
Giovanni Staurenghi,
Peter Wiedemann,
Sebastián Wolf,
Shiao Hui Melissa Liew,
Sabine Desset-Brèthes,
Harry Staines,
Jun Li,
Timothy Y Y Lai
Publication year - 2021
Publication title -
retinal cases and brief reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 14
eISSN - 1937-1578
pISSN - 1935-1089
DOI - 10.1097/icb.0000000000000825
Subject(s) - medicine , ranibizumab , choroidal neovascularization , ophthalmology , subgroup analysis , bevacizumab , macular degeneration , meta analysis , chemotherapy
To evaluate the efficacy and safety of ranibizumab 0.5 mg in adolescent patients with any choroidal neovascularization etiology enrolled in the 12-month MINERVA study.